These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 54211)

  • 21. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
    Presant CA; Vietti TJ; Valeriote F; Coulter DM
    J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic antitumor effect of fluoropyrimidines and polyinosinic-polycytidylic acid against L1210 leukemia.
    Iigo M; Chapekar MS; Glazer RI
    Cancer Res; 1985 Sep; 45(9):4039-42. PubMed ID: 2411395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
    Lomen PL; Khilanani P; Kessel D
    Neoplasma; 1980; 27(1):101-6. PubMed ID: 6154898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice.
    Presant CA; Coulter D; Valeriote F; Vietti TJ
    J Natl Cancer Inst; 1981 Jun; 66(6):1151-4. PubMed ID: 6165854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
    Beisler JA; Abbasi MM; Kelley JA; Driscoll JS
    J Med Chem; 1977 Jun; 20(6):806-12. PubMed ID: 69026
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis.
    Grant S; Bhalla K; Gleyzer M
    Cancer Res; 1984 Dec; 44(12 Pt 1):5505-10. PubMed ID: 6208998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin.
    Plagemann PG; Behrens M; Abraham D
    Cancer Res; 1978 Aug; 38(8):2458-66. PubMed ID: 78761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of intravenous infusion of 5-aza-2'-deoxycytidine on survival time of mice with L1210 leukemia.
    Momparier RL; Gonzales FA
    Cancer Res; 1978 Sep; 38(9):2673-8. PubMed ID: 79443
    [No Abstract]   [Full Text] [Related]  

  • 29. Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine.
    Heby O; Russell DH
    Cancer Res; 1973 Jan; 33(1):159-65. PubMed ID: 4118428
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
    Wong PP; Currie VE; Mackey RW; Krakoff IH; Tan CT; Burchenal JH; Young CW
    Cancer Treat Rep; 1979 Aug; 63(8):1245-9. PubMed ID: 383291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of uridine kinase in different lines of AKR leukemic mice and its relation to chemotherapy with 5-azacytidine.
    Vesely J
    Int J Cancer; 1974 Dec; 14(6):826-32. PubMed ID: 4142789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological evaluation of stability of 5-azacytidine.
    Li LH; Buskirk HH; Blowers CL; Neil GL; Hanka LJ
    J Antibiot (Tokyo); 1984 Apr; 37(4):419-21. PubMed ID: 6202669
    [No Abstract]   [Full Text] [Related]  

  • 33. Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.
    Sirotnak FM; Poser RE; Barrueco JR
    Cancer Res; 1987 Oct; 47(20):5334-9. PubMed ID: 3498533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
    Lavelle D; Vaitkus K; Ling Y; Ruiz MA; Mahfouz R; Ng KP; Negrotto S; Smith N; Terse P; Engelke KJ; Covey J; Chan KK; Desimone J; Saunthararajah Y
    Blood; 2012 Feb; 119(5):1240-7. PubMed ID: 22160381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the urinary metabolites of 5-azacytidine in mice.
    Kelly CJ; Coles E; Gaudio L; Yesair DW
    Biochem Pharmacol; 1980 Feb; 29(4):609-15. PubMed ID: 6154465
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice.
    Zaharko DS; Covey JM
    Cancer Treat Rep; 1984 Oct; 68(10):1255-64. PubMed ID: 6084549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.
    Driscoll JS; Johns DG; Plowman J
    Invest New Drugs; 1985; 3(4):331-4. PubMed ID: 2417984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
    Furner RL; Mellett LB; Herren TC
    J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
    Chabot GG; Momparler RL
    Cancer Treat Rep; 1984 Dec; 68(12):1483-7. PubMed ID: 6210142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
    Von Hoff DD; Slavik M; Muggia FM
    Ann Intern Med; 1976 Aug; 85(2):237-45. PubMed ID: 60073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.